The estimated Net Worth of Norman H Pessin Brian L. Pe... is at least $530 Mille dollars as of 16 August 2016. Norman Pe owns over 36,250 units of Chembio Diagnostics stock worth over $530,066 and over the last 8 years Norman sold CEMI stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Norman Pe CEMI stock SEC Form 4 insiders trading
Norman has made over 1 trades of the Chembio Diagnostics stock since 2016, according to the Form 4 filled with the SEC. Most recently Norman bought 36,250 units of CEMI stock worth $198,650 on 16 August 2016.
The largest trade Norman's ever made was buying 36,250 units of Chembio Diagnostics stock on 16 August 2016 worth over $198,650. On average, Norman trades about 36,250 units every 0 days since 2016. As of 16 August 2016 Norman still owns at least 1,152,317 units of Chembio Diagnostics stock.
You can see the complete history of Norman Pe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Chembio Diagnostics
Over the last 20 years, insiders at Chembio Diagnostics have traded over $909,824 worth of Chembio Diagnostics stock and bought 3,754,893 units worth $1,696,058 . The most active insiders traders include Credit Advisors, Llcpercept..., Lawrence A. Siebert e Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of $36,203. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth $109,552.
What does Chembio Diagnostics do?
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
What does Chembio Diagnostics's logo look like?
Complete history of Norman Pe stock trades at Chembio Diagnostics
Chembio Diagnostics executives and stock owners
Chembio Diagnostics executives and other stock owners filed with the SEC include:
-
Javan Esfandiari,
Exec. VP and Chief Science & Technology Officer -
Richard L. Eberly,
Pres, CEO & Director -
Javan Esfandiari,
Executive Vice President, Chief Scientific And Technology Officer -
Neil Goldman,
Chief Financial Officer, Executive Vice President -
Katherine Davis,
Independent Director -
John Potthoff,
Independent Director -
Gail Page,
Executive Chairman of the Board -
Mary Polan,
Independent Director -
Lynn Lewis,
Investor Relations Contact Officer -
Chuck Caso,
Vice President of Sales and Marketing for North America -
Richard Eberly,
President, Chief Executive Officer, Director -
Stella Rivera,
VP of HR -
Atif Rizvi,
VP of Fin. -
Dr. Konstantin Lyashchenko,
Research Director of Chembio Diagnostic Systems Inc -
Charles Caso,
VP of Sales & Marketing -
Paul J. Angelico,
VP of Global Operations -
Peter Kissinger,
Director -
Richard J Larkin,
Chief Financial Officer -
Barbara A De Buono,
Director -
John J Iii Sperzel,
CEO -
Robert L Aromando,
Sr VP, Commercial Operations -
Alan Carus,
Director -
Lawrence A. Siebert,
President -
Leslie Teso Lichtman,
-
Norman H Pessin Brian L. Pe...,
-
Gary Meller,
Director -
Sharon W Klugewicz,
Chief Operating Officer -
David Gyorke,
See Remarks -
Robert Passas,
See Remarks -
Avi Pelossof,
Vice President -
Gerald A Eppner,
Director -
James D Merselis,
Director -
Capital Master Llc Crestvie...,
-
David Acheson,
-
Credit Advisors, Llcpercept...,
-
David William Bespalko,
-
Lawrence J. Steenvoorden,
See remarks -
Charles Caso,
See Remarks -
Paul Angelico,
See remarks